Results 121 to 130 of about 416,036 (340)

Photoactivated Proximity Protein Labeling Reveals Enhanced Tumor Retention of a D‐Peptide‐Ruthenium Prodrug Conjugate

open access: yesAdvanced Healthcare Materials, EarlyView.
Six stereoisomeric ruthenium‐peptide conjugates were synthesized and characterized, which showed high potential in photoactivated chemotherapy (PACT) and proximity protein labeling. Abstract Amino acid chirality is known to influence the biological properties of peptide‐containing prodrugs.
Liyan Zhang   +7 more
wiley   +1 more source

Pomegranate juice protects kidneys from Cisplatin-induced nephrotoxicity

open access: yesمجلة كلية الطب, 2018
Background: Cisplatin is a potent anti-cancer agent used successfully in treatment of cancers of solid organs, but it has a high rate of nephrotoxicity.
Hussain A. Aljebori   +2 more
doaj   +1 more source

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting [PDF]

open access: yes, 2019
The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of ...
Girard, N   +4 more
core   +1 more source

Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk

open access: yesAdvanced Healthcare Materials, EarlyView.
Centralizes the microbiome within 3D tumor‐microbiome model platforms, including spheroids, organoids, 3D‐bioprinted constructs, and microfluidic chips, each enabling structured host‐tumor‐microbe studies. These systems support bacterial colonization, facilitating investigation of microbial impacts on tumor growth, immunity, and therapy. The microbiome
Marina Green Buzhor   +12 more
wiley   +1 more source

Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the eortc malignant melanoma cooperative group [PDF]

open access: bronze, 1988
Claire F. Verschraegen   +8 more
openalex   +1 more source

Beyond Cisplatin – I

open access: yesBladder Cancer, 2016
Roughly 25% of patients at diagnosis of urothelial cancer (UC) have at least muscle invasive disease [1] and about half of these have extravesical extension or more advanced disease at that time. Additionally 10–15% of patients who initially have non-muscle invasive UC will subsequently develop muscle invasive or more advanced cancer.
openaire   +4 more sources

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

open access: yes, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA   +17 more
core   +3 more sources

Engineered Plasmonic and Fluorescent Nanomaterials for Biosensing, Motion, Imaging, and Therapeutic Applications

open access: yesAdvanced Materials, EarlyView.
A schematic illustration of how noble metals can be used to create nanoparticles (NPs) or nanoclusters (NCs). Noble metal NPs, due to their plasmonic properties, enable photothermal therapy and surface‐enhanced Raman scattering (SERS). In contrast, NCs, which lack a plasmonic resonance band, exhibit fluorescence, making them ideal for bioimaging ...
David Esporrín‐Ubieto   +3 more
wiley   +1 more source

Long-term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy [PDF]

open access: bronze, 1986
Sophie D. Fosså   +4 more
openalex   +1 more source

Mechanisms of cross resistance between cisplatin and bleomycin in saccharomyces cerevisiae [PDF]

open access: yes, 2019
Tumor cells can simultaneously acquire resistance against a diverse group of drugs. This phenomenon is called pleotropic resistance or multidrug resistance.
Burgos-Molina, Antonio Manuel   +2 more
core  

Home - About - Disclaimer - Privacy